Register now to R3i !
Your Login
Your Password
Confirm Password  
Your Email
26 august 2017, Barcelona, Spain
ESC 2017: New approaches to targeting residual cardiovascular risk
Read full report..
R3i editorial
10 January 2018

Prof. Jean Charles Fruchart, Prof. Michel Hermans, Prof. Pierre Amarenco
Addressing residual cardiovascular risk – back to basics?

While 2017 has certainly been a ‘rollercoaster of a year’ for lipid research, it has also provided important insights for the management of residual cardiovascular risk.
The FOURIER (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk) trial was the first to lead the attack, demonstrating incremental benefit with a ‘lower is better’ approach targeting low-density lipoprotein cholesterol (LDL-C) with the PCSK9 inhibitor evolocumab in patients with stable atherosclerotic cardiovascular disease (ASCVD) on intensive statin therapy.
The landmark trial, CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcomes Study), followed up in providing proof-of-concept for the relevance of targeting residual inflammatory risk with canakinumab...
landmark study
10 January 2018

COMPASS: targeting residual cardiovascular risk in stable atherosclerotic vascular disease Read more...

This month’s Landmark article focuses on strategies to address residual cardiovascular risk beyond lipid-lowering therapy. Notably, long-term aspirin has been shown to significantly improve both fatal and non-fatal vascular events in people with established ASCVD (1). While previous studies have highlighted additional benefit with combination...
focus on...
10 January 2018

Triglycerides in risk prediction in primary prevention

Elevated triglycerides – a marker of levels of triglyceride-rich lipoproteins and their remnants - as a causal factor in ASCVD has gained renewed focus, with accumulating evidence from observational and genetic studies (1,2). Now, this analysis from the Copenhagen General Population Study has defined the...
R3i Activities Highlights
10 -12 june 2017, St Petersburg, Russia
MSDA 2017 - 12th Metabolic Syndrome, type II Diabetes and Atherosclerosis Congress
Read full report..
recent publication

HDL and infection

The concept of raising high-density lipoprotein (HDL) cholesterol using pharmacological intervention to reduce cardiovascular risk has been discredited with a...
recent publication

Triglycerides and Alzheimer’s disease?

This study implies that increased levels of triglycerides in middle-aged individuals may be implicated in the subsequent pathology of Alzheimer’s...
recent publication

Plaque profile in diabetes

According to this study, individuals with diabetes mellitus have a more advanced arterial plaque phenotype than those without diabetes, and...
recent publication

Empagliflozin decreases remnant cholesterol in diabetes patients

Empagliflozin, a potent and highly selective sodium-glucose co-transporter-2 (SGLT-2) inhibitor of the proximal tubule, has previously been shown to significantly...
PCSK9 and Atherosclerosis
Downloadable slidekit
PCSK9 downloadable slidekit
Created by Professors Jean Davignon (Vice-President of the R3i foundation), Jean-Charles Fruchart (President of R3i) and Michel Hermans (R3i General Secretary), the latest downloadable deck of 242 slides discusses the potential role for anti-PCSK9 mAbs in the future management of cardiovascular disease.
SSPARMa at the Crossroads of Obesity, Diabetes and Cardiovascular Diseases
Downloadable slidekit
PCSK9 downloadable slidekit
Created by Professor Jean-Charles Fruchart, President of the R3i foundation, this downloadable library of 238 slides discusses the rationale and therapeutic opportunities for SPPARαMs in the future management of cardiovascular diseases.

What is residual risk ?

Residual risk of vascular events persisting in patients at treatment goals according to current standards of care or failing to meet goals, including risk related to dyslipidemia, high blood pressure, hyperglycemia, systemic inflammation and unhealthy lifestyles.

What is the Initiative ?

The R3i, a worldwide, academic, multidisciplinary non-profit organization, aims to successfully address the excessively high risk of macro- and micro-vascular complications in patients with atherogenic dyslipidemia, characterised by elevated triglycerides and low levels of high-density lipoprotein (HDL) cholesterol and unaddressed by current standards of care.